34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrogen receptor-positive breast cancer, but markers predictive of treatment failure have not been identified. Here, we generated gene expression profiles of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen monotherapy. An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which outperformed existing biomarkers. Ectopic expression of HOXB13 in MCF10A breast epithelial cells enhances motility and invasion in vitro, and its expression is increased in both preinvasive and invasive primary breast cancer. The HOXB13:IL17BR expression ratio may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer.

          Related collections

          Author and article information

          Journal
          Cancer Cell
          Cancer cell
          Elsevier BV
          1535-6108
          1535-6108
          Jun 2004
          : 5
          : 6
          Affiliations
          [1 ] Arcturus Bioscience, Inc., 2715 Loker Avenue West, Carlsbad, CA 92008, USA.
          Article
          S1535610804001412
          10.1016/j.ccr.2004.05.015
          15193263
          8def78e2-d77a-4677-85e2-cc7f71efc67d
          History

          Comments

          Comment on this article